Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

Clinical trial NCT02714595 · COMPLETED

Trial details

NCT number: NCT02714595
Sponsor: Shionogi
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Healthcare-associated Pneumonia (HCAP)Bloodstream Infections (BSI)Hospital Acquired Pneumonia (HAP)Complicated Urinary Tract Infection (cUTI)Sepsis Ventilator Associated Pneumonia (VAP)

Start date: 2016-09-07
Primary completion: 2019-04-01
Enrollment: 152

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.